Essential Healthcare News
SEE OTHER BRANDS

Global take on healthcare and wellness news

Essential Healthcare News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.

Press releases published on April 24, 2025

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to …

Magnolia Dental Introduces Eco-Friendly Dentistry for a Greener Future

Magnolia Dental Introduces Eco-Friendly Dentistry for a Greener Future

Magnolia Dental leads the way in Eco-Friendly Dentistry with sustainable practices, reducing waste and promoting green dental care for a healthier future. WATERDOWN, HAMILTON, CANADA, April 24, 2025 /⁨EINPresswire.com⁩/ -- A dentist’s office reminds most …

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8 …

HCI Group Declares Quarterly Cash Dividend

HCI Group Declares Quarterly Cash Dividend

TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- The board of directors of HCI Group, Inc. (NYSE: HCI) has declared a regular quarterly cash dividend in the amount of 40 cents per common share. The dividend is scheduled to be paid June 20, 2025 to …

Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025

LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and …

NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025

NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025

TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a first installment of €130 million and (ii) the debt …

GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société

GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société

Trésorerie et équivalents de trésorerie s’élevant à 81,8 millions d’euros au 31 décembre 2024. En outre, conclusion, en début d’année (i) d’un accord de royalty financing non dilutif d'un montant maximum de 185 millions d'euros comprenant un versement …

Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The …

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to …

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections  Using gaseous Nitric Oxide (gNO)

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …

Treace to Report First Quarter 2025 Financial Results on May 8, 2025

Treace to Report First Quarter 2025 Financial Results on May 8, 2025

PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …

Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it …

FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances

FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development …

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 …

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

First Quarter Highlights† Reported revenue of $355.4 million, up 9.8% Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectively GAAP operating margin of 11.5%, compared to 11.1% in prior year period Non-GAAP …

Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society

Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society

Fort Mill, S.C., April 24, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their …

PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation …

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological …

Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor

Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor

► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service